Aquestive(AQST) - 2024 Q1 - Quarterly Report

Product Development and Clinical Trials - The company aims to file the NDA for Anaphylm™ (epinephrine) Sublingual Film with the FDA before the end of 2024, following a pre-NDA meeting expected in the second half of 2024[104]. - Anaphylm has shown clinical results comparable to auto-injectors for the emergency treatment of allergic reactions, with positive topline data from multiple studies reported in 2022 and 2023[103]. - The pivotal clinical study for Anaphylm commenced in Q4 2023, with the FDA providing clarity on the study design and endpoints[103]. - The company is conducting additional studies for Anaphylm, including a temperature/pH study expected to complete in Q2 2024 and a pediatric study planned for the second half of 2024[103]. - AQST-108, a sublingual film composed of the prodrug dipivefrin, is in development and is expected to provide an alternative delivery method for epinephrine[104]. - AQST-108, a sublingual film formulation for systemic epinephrine, has shown rapid absorption in preclinical trials and is being developed for various dermatological conditions[105]. - The FDA granted Fast Track designation for Anaphylm in March 2022, indicating the product's potential to address unmet medical needs[103]. - The company reported no serious adverse events in clinical studies for Anaphylm, indicating a favorable safety profile[103]. Financial Performance - The licensed product portfolio generated $50.6 million in revenue for the year ended December 31, 2023, compared to$ 47.7 million in 2022, with Q1 2024 revenue at $12.1 million, up from$ 11.1 million in Q1 2023[107]. - Total revenues for the three months ended March 31, 2024, increased by 8% or $919, reaching$ 12,053 compared to $11,134 in the same period of 2023[126]. - Manufacture and supply revenue rose by approximately 8% or$ 756, totaling $10,518, driven by a 24% increase in Suboxone revenue and a 27% increase in Sympazan revenue[128]. - License and royalty revenue increased by 23% or$ 213, reaching $1,132, primarily due to a 158% increase in royalty revenues from Azstarys and a 28% increase from Sympazan[128]. Expenses and Costs - Research and development expenses surged by 67% or$ 2,385, totaling $5,932, mainly due to clinical trial costs for the Anaphylm program[129]. - Selling, general and administrative expenses rose by 43% or$ 3,234, amounting to $10,689, reflecting increased operational costs[129]. - Interest expense increased by 94% or$ 1,349, totaling $2,784, indicating higher borrowing costs[129]. - Total project expenses for Anaphlym increased 85%, or$ 1,446, for the three months ended March 31, 2024, compared to the same period in 2023[131]. - Clinical trial expenses for Anaphlym rose 113%, or $1,579, to$ 2,975 for the three months ended March 31, 2024, primarily due to ongoing clinical trial costs[131]. - Selling, general and administrative expenses increased 43%, or $3,234, for the three months ended March 31, 2024, compared to the same period in the prior year[131]. Cash Flow and Financing - The company had$ 95,200 in cash and cash equivalents as of March 31, 2024, providing liquidity for operating needs for at least the next twelve months[132]. - For the three months ended March 31, 2024, net cash used for operating activities was $(10,384), a decrease of$ 19,200 compared to the same period in 2023[135][136]. - The company completed an Underwritten Public Offering of 16,666,667 shares at a price of $4.50 per share, resulting in gross proceeds of$ 75,000 and net proceeds of $70,500 after underwriting discounts[139]. - Net cash provided by financing activities for the three months ended March 31, 2024, was$ 81,741, an increase of $90,946 compared to the same period in 2023[135][138]. - The company plans to use net proceeds from recent transactions to advance the development of its product pipeline, including Anaphylm and Libervant[139]. Debt and Financial Risks - The company has a significant level of debt with ongoing interest payments and principal repayments starting in June 2026[140]. - The ability to secure additional equity financing is influenced by operating performance, regulatory approval processes, existing debt levels, and market conditions[141]. - If adequate funds are not available, the company may need to reduce staff, delay or discontinue research and development programs, and significantly cut spending[141]. - The company may face dilution of stockholder rights if additional equity securities are issued, which could adversely affect stockholder interests[141]. Regulatory and Market Position - The company remains a smaller reporting company, allowing it to take advantage of certain disclosure exemptions[111]. - As a smaller reporting company, the company is not required to provide detailed market risk disclosures[143].